SS
LPCN icon

SBI Securities’s Lipocine LPCN Stock Holding History

SBI Securities’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$535 Hold
67
– – ﹤0.01% 2875
2025
Q4 		$538 Hold
67
– – ﹤0.01% 2848
2025
Q3 		$191 Hold
67
– – ﹤0.01% 3331
2025
Q2 		$212 Hold
67
– – ﹤0.01% 3287
2025
Q1 		$213 Buy
+67
New +$259 ﹤0.01% 3208

Other funds holding LPCN

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
SFCM
Seven Fleet Capital Management Mountain View, California $318M AUM
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

SBI Securities's LPCN Position: Q1 2026 in Review

SBI Securities held its Lipocine (LPCN) position steady in Q1 2026 at 67 shares worth $535. The position accounts for ﹤0.01% of the portfolio, ranked #2875.

SBI Securities first reported a position in LPCN in Q1 2025 and has held it in 5 quarters since. The position peaked at $538 in Q4 2025. 47 funds tracked by Wall St. Rank hold LPCN as of Q1 2026.

  • SBI Securities held 67 shares of Lipocine worth $535 as of Q1 2026.
  • SBI Securities left its Lipocine share count unchanged in Q1 2026.
  • Lipocine made up ﹤0.01% of SBI Securities's portfolio in Q1 2026, its #2875 holding.
  • SBI Securities first reported a position in Lipocine in Q1 2025 and has held it in 5 quarters since.
  • SBI Securities's Lipocine position peaked at $538 in Q4 2025.
  • 47 funds tracked by Wall St. Rank held Lipocine as of Q1 2026.

Based on SBI Securities's 13F filing for Q1 2026, filed 28 Apr 2026.